ABSTRACT
Objective To evaluate prospectively the side effects and tolerance of docetaxel with concurrent late-course hyperfractionated radiotherapy after breast-conserving surgery for stage T1-T2 breast cancer, and to assess the value of this treatment in shortening the treatment time and reducing the economic burden among patients. Methods A total of 20 patients with T1-T2 breast cancer were recruited after they underwent breast-conserving surgery. The acute radiation response classification, treatment completion rate, disease-free survival, hospital stays, and treatment costs were observed. Radiotherapy for all patients was started before the last single-agent docetaxel chemotherapy. Results The completion rate of treatment and the good rate of cosmetic effect reached 100%. The main adverse reactions were hematological toxicity (leukopenia) and skin reactions, which were tolerated. The median follow-up time was 30.1 months, and the follow-up rate was 100%. The average total treatment time of this hyperfractionated radiotherapy with concurrent docetaxel was four weeks, and the total hospitalization cost savings was approximately 10, 000 yuan. The 21-month disease-free survival rate was 100%. Conclusion Stage T1-T2 breast cancer can tolerate hyperfractionated radiotherapy with concurrent chemotherapy after a breast-conserving operation. The procedure results in good local control and satisfactory cosmetic effects, with high health and economic value.
ABSTRACT
Purpose:To analyze the prognostic factors of testicular seminoma.Materials and Methods:133 patients with testicular seminoma histologically proved were treated from October, 1975 to December,1990. Most of them were firstly treated with orchiectomy and minority were treated with orchiectomy plus lymphadenectomy in abdomen cavity. All patients were treated with postoperative radiotherapy and a little part of them were combined with irregular chemotherapy. Results: The overall 5-year survival rates were:92.5(65/70) for stage Ⅰ, 52.6(10/19) for stageⅡ, 25%(4/16) for stage Ⅲ and 22.2%(2/9) for stage Ⅳ. Patients received radiation dose of 20～30Gy gave a five year survival rate of 80% which was much better than those who received radiation dose 30Gy(P